Pharma Pioneer

Approval Granted to Brain Trust Bio for Phase I Trials of Novel IT Drug Delivery for ALS and CNS Conditions

19 May 2024
2 min read

Brain Trust Bio (BTB), a pioneering company in the field of central nervous system (CNS) disease treatment, has been granted the go-ahead to initiate Phase I clinical trials for its innovative Continuous Intrathecal Drug Delivery Method in Australia. This approval aligns with U.S. standards, which means that the trial results will be immediately recognized in the United States, allowing BTB to progress directly to Phase II trials without any need for redundant testing. This advancement is a significant step towards a groundbreaking treatment for severe neurological conditions, such as amyotrophic lateral sclerosis (ALS).
BTB is dedicated to the innovation of therapeutic strategies for CNS diseases. By refining an FDA-approved treatment, the company's patented drug delivery method is designed to enhance the effectiveness of IT-Riluzole, the sole medication proven to extend life in ALS patients, by delivering it directly to the CNS. This approach targets the cerebrospinal fluid (CSF), circumventing the blood-brain barrier and enabling a fivefold increase in targeted delivery with reduced dosages. This method not only boosts neuroprotective potential but also minimizes side effects, presenting a hopeful direction for CNS treatment advancements.
Chen Benkler, Ph.D., Co-Founder and CEO of BTB, emphasized the importance of this approval, stating, "Our proposed treatment provides a unique opportunity for CSF sampling, offering a depth of biomarker data that has not been previously possible, which will greatly improve our understanding and treatment of CNS diseases." Early applications of BTB's method have shown promise, with two patients treated for over two years experiencing no adverse effects, suggesting the potential to extend life and improve quality of life. The upcoming trials, focusing on IT-Riluzole, will further explore the method's capabilities in treating CNS diseases.
The clinical trials will include 10 patients and will be conducted over six months at two renowned Australian medical institutions: Flinders University in Adelaide and Sunshine Coast Hospital in Birtinya. These trials will be overseen by top medical experts, ensuring rigorous clinical standards are maintained. F

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Astria Reports Favorable STAR-0215 Phase 1b/2 HAE Trial Outcomes
Pharma Pioneer
3 min read
Astria Reports Favorable STAR-0215 Phase 1b/2 HAE Trial Outcomes
19 May 2024
Astria Therapeutics has reported promising preliminary results from the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215.
Read →
Stoke Therapeutics Unveils Pivotal STK-001 Data for Dravet Syndrome Treatment
Pharma Pioneer
3 min read
Stoke Therapeutics Unveils Pivotal STK-001 Data for Dravet Syndrome Treatment
19 May 2024
Stoke Therapeutics has reported significant findings from its Phase 1/2a clinical trials and open-label extension studies for STK-001.
Read →
Rhythm Pharma Initiates Phase 1 Study with First Dose of Weekly MC4R Agonist RM-718
Pharma Pioneer
2 min read
Rhythm Pharma Initiates Phase 1 Study with First Dose of Weekly MC4R Agonist RM-718
19 May 2024
Rhythm Pharmaceuticals has commenced dosing for its Phase 1 clinical trial of RM-718.
Read →
Valneva Launches Phase 1 Study for Zika Vaccine Candidate
Pharma Pioneer
3 min read
Valneva Launches Phase 1 Study for Zika Vaccine Candidate
19 May 2024
Valneva SE launched a Phase 1 clinical study to evaluate the safety and ability to provoke an immune response of their Zika virus vaccine candidate, VLA1601.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.